EP0666734A1 - Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis - Google Patents

Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis

Info

Publication number
EP0666734A1
EP0666734A1 EP93924089A EP93924089A EP0666734A1 EP 0666734 A1 EP0666734 A1 EP 0666734A1 EP 93924089 A EP93924089 A EP 93924089A EP 93924089 A EP93924089 A EP 93924089A EP 0666734 A1 EP0666734 A1 EP 0666734A1
Authority
EP
European Patent Office
Prior art keywords
propylene glycol
dandruff
concentration
composition
scalp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93924089A
Other languages
German (de)
French (fr)
Inventor
Michael Potts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surtech International Ltd
Original Assignee
Beiersdorf AG
Surtech International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG, Surtech International Ltd filed Critical Beiersdorf AG
Publication of EP0666734A1 publication Critical patent/EP0666734A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations

Definitions

  • This invention relates to a method and composition for the prevention and/or treatment of scaling conditions of the scalp, such as dandruff, seborrhoeic dermatitis and psoriasis.
  • Previously known methods for preventing and treating dandruff generally involve applying to the scalp various anti-dandruff agents contained in lotions, gels and shampoos.
  • anti-dandruff agents include sulphur and selenium compounds, zinc pyrrithione and bacteriostatic and bacteriacidal agents such as, for example, hexachlorophene.
  • the use of such anti-dandruff agents can give rise to adverse reactions, for example allergic reactions and erythematous lesions. Consequently, known anti-dandruff agents cannot be used in the long term and it is frequently found that dandruff symptoms recur.
  • Known anti-dandruff agents are often difficult to formulate into cosmetically acceptable compositions.
  • UK Patent No. GB 2,205,743 described the finding that propylene glycol is effective as an anti-dandruff agent and that a significant anti-dandruff effect may be observed following application of propylene glycol to the scalp, e.g. in the form of a lotion, gel or shampoo.
  • Propylene glycol when used in accordance with the teachings of GB 2,205.7 ⁇ 3. avoided undesirable side effects which occur following use of known anti-dandruff agents.
  • Propylene glycol has hitherto also been described for use as a diluent, thinning agent or vehicle for various pharmaceutical products including such products intended for topical use.
  • US-A-3,984,866 describes the use of certain alpha-substituted carboxylic acid derivatives as active ingredients for treating keratinization defects.
  • DE-A-2,75 ⁇ . ⁇ 8 i * describes the use of chenodesoxic acid as the active ingredient of anti-dandruff compositions including lotions, gels and shampoos.
  • This specification mentions propylene glycol as an ingredient of such compositions but not as an active ingredient.
  • DE-A-1,792,154 describes anti-dandruff cosmetic compositions containing as active ingredient, inter alia arginine or arginine citrate.
  • Such compositions can contain relatively small proportions of propylene glycol as diluent along with relatively larger proportions of ethanol.
  • GB-A-l,l4 ⁇ ,443 describes an antiseptic composition consisting of a saturated solution of salicylic acid in propylene glycol and in addition an antiseptic selected from sodium dibromoxymercurifluorescein, sodium ethylmercurithio salycylate, iodine/sodium iodide mixtures and polyvinyl pyrrolidone-iodine complex.
  • the compositions of GB-A-1,1 ⁇ 0,443 generally contained more than 10 wt % of salicylic acid and the patent is not concerned at all with treatment of dandruff or seborrhoeic dermatitis.
  • a possible reason for the actions of the combination therapy of the invention is that combinations of propylene glycol and salicylic acid have enhanced activity against Pityrosporum ovale. an organism that is now thought to be implicated as an aetiological a responsible for both psoriasis and seborrhoeic dermatitis and poss also dandruff. Further the combinations of propylene glycol and salicylic acid exhibit an enhanced keratolytic action.
  • composition for use in the treatment of scaling conditions of the scalp including dandruff, seborrhoeic dermatitis and psoriasis wh comprises as active ingredients, propylene glycol and salycylic ac together with a topically acceptable excipient, the propylene glyc being present in a concentration of not greater than 50 wt % and t salicylic acid being present in a concentration of not greater tha t %.
  • the concentration of propylene glycol is from to 50 wt %, most preferably from 10 to 40 wt %.
  • the salicylic acid is preferably present in a concentrat of from 1 to 6 wt U, most preferably from 1 to wt %.
  • compositions according to the invention may be formulated in the form of solutions, lotions or gels suitable for topical application, or in the form of a shampoo.
  • Compositions according to the invention may contain any conventional incidental adjuvents, for example, emolients, thickening agents, foaming agen perfumes, colouring agents, stabilising agents, pH-ad usting agent and preservatives as well as water and/or ethanol.
  • Shampoos in accordance with the invention typically cont conventional detergent and/or s rfactants to provide any necessary foaming and cleansing action.
  • the shampoos will contain perfuming ingredients and colouring agents and if desired other ag to make the product cosmetically acceptable, e.g. pearling agents, thickeners etc.
  • a method of treating dandruff and/or seborrhoeic dermatit and/or psoriasis which comprises applying a composition according the invention to the affected region.
  • the compositions may be applied to the affected region at regular intervals of, for example. 1-5 and preferably 1-10 days.
  • the shampoo should be left on the hair, for example, for 1-5 minutes to enable the therapeutic effects of the proplylene glycol and salicylic acid to occur.
  • a lotion or gel also in accordance with the invention should be rubbed into the scalp and left in situ for 10 to 15 minutes. This combination of treatments has been found further to enhance the efficacy of the combination therapies of the invention.
  • the invention thus further provides a kit for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis, comprising
  • a specific combination therapy according to the invention comprises

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

A composition for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprises as active ingredients, propylene glycol and salicylic acid, together with a topically acceptable excipient, the propylene glycol being present in a concentration of not greater than 50 wt % and the salicylic acid being present in a concentration of not greater than 10 wt %.

Description

METHOD AND COMPOSITION FOR PREVENTION ANP/OR TREATMENT OF DANDRUFF AND
SEBORRHOEIC DERMATITIS
This invention relates to a method and composition for the prevention and/or treatment of scaling conditions of the scalp, such as dandruff, seborrhoeic dermatitis and psoriasis.
Previously known methods for preventing and treating dandruff generally involve applying to the scalp various anti-dandruff agents contained in lotions, gels and shampoos. Examples of such anti-dandruff agents include sulphur and selenium compounds, zinc pyrrithione and bacteriostatic and bacteriacidal agents such as, for example, hexachlorophene. In many individuals, the use of such anti-dandruff agents can give rise to adverse reactions, for example allergic reactions and erythematous lesions. Consequently, known anti-dandruff agents cannot be used in the long term and it is frequently found that dandruff symptoms recur. Known anti-dandruff agents are often difficult to formulate into cosmetically acceptable compositions.
Known treatments for seborrhoeic dermatitis and psoriasis generally involve the use of corticosteriods or other pharmacologically active agents which have a profound metabolic effect.
UK Patent No. GB 2,205,743 described the finding that propylene glycol is effective as an anti-dandruff agent and that a significant anti-dandruff effect may be observed following application of propylene glycol to the scalp, e.g. in the form of a lotion, gel or shampoo. Propylene glycol, when used in accordance with the teachings of GB 2,205.7^3. avoided undesirable side effects which occur following use of known anti-dandruff agents. Propylene glycol has hitherto also been described for use as a diluent, thinning agent or vehicle for various pharmaceutical products including such products intended for topical use. Thus
US-A-3,984,866 describes the use of certain alpha-substituted carboxylic acid derivatives as active ingredients for treating keratinization defects.
Similarly DE-A-2,75δ.^8i* describes the use of chenodesoxic acid as the active ingredient of anti-dandruff compositions including lotions, gels and shampoos. This specification mentions propylene glycol as an ingredient of such compositions but not as an active ingredient.
DE-A-1,792,154 describes anti-dandruff cosmetic compositions containing as active ingredient, inter alia arginine or arginine citrate. Such compositions can contain relatively small proportions of propylene glycol as diluent along with relatively larger proportions of ethanol.
GB-A-l,l4θ,443 describes an antiseptic composition consisting of a saturated solution of salicylic acid in propylene glycol and in addition an antiseptic selected from sodium dibromoxymercurifluorescein, sodium ethylmercurithio salycylate, iodine/sodium iodide mixtures and polyvinyl pyrrolidone-iodine complex. The compositions of GB-A-1,1^0,443 generally contained more than 10 wt % of salicylic acid and the patent is not concerned at all with treatment of dandruff or seborrhoeic dermatitis.
It has now been found that the anti-dandruff activity of propylene glycol can be synergistically enhanced by combining it with relatively low concentrations of salicylic acid (which itself, in such concentrations, would have a negligible anti-dandruff action). Further such combinations have been found to be especially effective against more serious scaling conditions of the scalp, such as seborrhoeic dermatitis and psoriasis.
A possible reason for the actions of the combination therapy of the invention is that combinations of propylene glycol and salicylic acid have enhanced activity against Pityrosporum ovale. an organism that is now thought to be implicated as an aetiological a responsible for both psoriasis and seborrhoeic dermatitis and poss also dandruff. Further the combinations of propylene glycol and salicylic acid exhibit an enhanced keratolytic action.
According to one aspect of the invention there is provid composition for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis wh comprises as active ingredients, propylene glycol and salycylic ac together with a topically acceptable excipient, the propylene glyc being present in a concentration of not greater than 50 wt % and t salicylic acid being present in a concentration of not greater tha t %.
Preferably the concentration of propylene glycol is from to 50 wt %, most preferably from 10 to 40 wt %.
The salicylic acid is preferably present in a concentrat of from 1 to 6 wt U, most preferably from 1 to wt %.
The compositions according to the invention may be formulated in the form of solutions, lotions or gels suitable for topical application, or in the form of a shampoo. Compositions according to the invention may contain any conventional incidental adjuvents, for example, emolients, thickening agents, foaming agen perfumes, colouring agents, stabilising agents, pH-ad usting agent and preservatives as well as water and/or ethanol.
Shampoos in accordance with the invention typically cont conventional detergent and/or s rfactants to provide any necessary foaming and cleansing action. Normally the shampoos will contain perfuming ingredients and colouring agents and if desired other ag to make the product cosmetically acceptable, e.g. pearling agents, thickeners etc.
According to a further aspect of the invention there is provided a method of treating dandruff and/or seborrhoeic dermatit and/or psoriasis which comprises applying a composition according the invention to the affected region. In carrying out the method of the invention, the compositions may be applied to the affected region at regular intervals of, for example. 1-5 and preferably 1-10 days. In the case of shampoos, the shampoo should be left on the hair, for example, for 1-5 minutes to enable the therapeutic effects of the proplylene glycol and salicylic acid to occur. Preferably, before shampooing, a lotion or gel also in accordance with the invention should be rubbed into the scalp and left in situ for 10 to 15 minutes. This combination of treatments has been found further to enhance the efficacy of the combination therapies of the invention.
The invention thus further provides a kit for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis, comprising
(1) a supply of a gel or lotion as defined herein, and
(2) a supply of a shampoo as defined herein.
A specific combination therapy according to the invention comprises
(1) applying a gel or lotion according to the invention to the scalp and leaving it in situ for from 1 to 20, preferably to 10 minutes, and
(2) washing the gel or lotion from the scalp using a shampoo according to the invention.
The following examples illustrate compositions according to the invention:
1. Hair Treatment Lotion t %
A. Water - deionised 41.800 Polymer JR125 0.700
B. Propylene Glycol Mono 25.000 Phenonip 0.500
C. Ethanol B 100 20.000 Propylene Glycol Mono 10.000 Salicylic Acid 2.000 2. Shampoo wt %
A. Water - deionised 20.000 Polymer JR30M 0.400
B. Water - deionised 1.400 Glucamate DOE 120 1.000
C. Empicol TL40T 30.000 Propylene Glycol Mono 25-000 Empigen BB 4.000 Tegobetain L7 6.000 Empilan CDE 5.000 Bronidox L 0.200
D. Propylene Glycol Mono 5-000 Salicylic Acid 2.000
Hair Treatment Lotion
100 g Lotion (or solution) contain
Salicylic Acid 2,00 g Ethanol 21,20 g
Propylene Glycol 35,00 g Polyquaternium-10 0,70 g Water 41,10 g
Shampoo wt %
Sodium Laureth Sulfate (25 wt %, with water)
Cocamidopropyl Betaine (30 wt %, with water)
Propylene Glycol
Salicylic Acid
PEG-120 Methylglucose Dioleate
Polyquaternium-10
Water

Claims

1. A composition for use in the treatment of scaling
conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprisesO as active ingredients, propylene glycol and salycylic acid, together with a topically acceptable excipient, the propylene glycol being present in a concentration of not greater than 50 wt % and the salicylic acid being present in a concentration of not greater than 10 wt % .
2. A composition according to Claim 1 wherein the propylene glycol is present in a concentration of from 5 to 50 wt % .
3. A composition according to Claim 2 wherein the propylene glycol is present in a concentration of from 10 to 40 wt % .
4. A composition according to any preceding claim wherein the salicylic acid is present in a concentration of from 1 to 6 wt %.
5- A composition according to Claim 4 wherein the salicylic acid is present in a concentration of from 1 to 3 wt % .
6. A composition according to any preceding claim wherein the topically acceptable excipients comprise water and/or ethanol.
7. A composition according to any preceding claim in the form of a lotion or gel.
8. A composition according to any of Claims 1 to 6 in the form of a shampoo.
9- A method for the prevention and/or treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprises applying to the scalp a composition as claimed in any preceding claim.
10. A method according to Claim 9 which comprises applying to the scalp of a lotion or gel as claimed in Claim 7. followed by washing the hair with a shampoo as claimed in Claim 8,
EP93924089A 1992-11-03 1993-11-02 Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis Withdrawn EP0666734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929223034A GB9223034D0 (en) 1992-11-03 1992-11-03 Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis
GB9223034 1992-11-03
PCT/EP1993/003060 WO1994009755A1 (en) 1992-11-03 1993-11-02 Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis

Publications (1)

Publication Number Publication Date
EP0666734A1 true EP0666734A1 (en) 1995-08-16

Family

ID=10724472

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93924089A Withdrawn EP0666734A1 (en) 1992-11-03 1993-11-02 Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis

Country Status (3)

Country Link
EP (1) EP0666734A1 (en)
GB (1) GB9223034D0 (en)
WO (1) WO1994009755A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681852A (en) * 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
CN1100532C (en) * 1993-11-12 2003-02-05 普罗克特和甘保尔公司 Desquamation compositions containing salicylic acid and zwitterionic compounds
CN1107495C (en) * 1994-07-01 2003-05-07 纺织研究院公司 Desquamation compositions
SE9403541L (en) * 1994-10-14 1996-04-15 Sven Moberg Antimicrobial composition
TW449485B (en) * 1995-03-31 2001-08-11 Colgate Palmolive Co Skin care products containing anti itching/anti irritant agents
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
FR2740679B1 (en) * 1995-11-03 1997-12-12 Letourneur Raymond SHAMPOO COMPOSITION AND TREATMENTS BASED ON RAINWATER
US5843875A (en) * 1996-06-20 1998-12-01 The Procter & Gamble Company Perfume delivery systems in liquid personal cleansing
US5804538A (en) * 1996-06-20 1998-09-08 The Procter & Gamble Company Perfume delivery systems in liquid personal cleansing compositions
DE10205193A1 (en) * 2002-02-08 2003-08-21 Beiersdorf Ag Cleaning preparations containing diol
FR2869797B1 (en) * 2004-05-10 2007-10-19 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION BASED ON A SURFACTANT, A MONOCARBOXYLIC ACID AND A POLYOL
FR2943896B1 (en) * 2009-04-01 2012-03-02 Oreal "ROLL-ON" HAS HIGH SALICYLIC ACID CONTENT.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53145925A (en) * 1977-05-23 1978-12-19 Kanebo Ltd Solid composition for softening corneous tissue
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
DD225913B1 (en) * 1984-06-22 1990-06-27 Miltitz Chem Werk ANTIBACTERIAL COMEDOLYTIC SUBSTANCE COMBINATION
FR2585575B1 (en) * 1985-08-01 1989-03-03 Pf Medicament PHARMACEUTICAL COMPOSITIONS WITH KERATOLYTIC ACTIVITY IN GEL FORM COMPRISING HYDROALCOHOLIC SALICYLIC ACID
SE462139B (en) * 1986-02-04 1990-05-14 Sven Moberg Pharmaceutical composition, containing propylene glycol and carbamide before treatment of BL.A. NAIL FUNGI AND SEBORROISIC ECSMA
DE3724691C2 (en) * 1987-07-25 1999-03-18 Konrad Minninger Pharmaceutical agent for the local therapy of flaking skin diseases
DE3811936A1 (en) * 1988-04-10 1989-10-19 Minninger Konrad DITHRANOL OIL

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9409755A1 *

Also Published As

Publication number Publication date
WO1994009755A1 (en) 1994-05-11
GB9223034D0 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
US10688117B2 (en) Topical wash composition for use in acne patients
ES2199470T3 (en) TOPICAL COMPOSITIONS TO REGULATE THE SKIN / GLOSSY ASPECT OF THE SKIN.
RU2647479C2 (en) Composition for face washing as emulsion containing benzoyl peroxide
CA1279576C (en) Treatment of skin disorders
US20060013845A1 (en) Oxygenated personal care products
DE2802924C2 (en) Medicines to treat acne
US20230055512A1 (en) Method of treatment of topical dermatologic acne using a cream composition and method of manufacture
US20110082118A1 (en) Onychomycosis Treatment Delivery System
US20090099257A1 (en) Composition and process for treating acne
US20080194662A1 (en) Cleanser composition
EP0666734A1 (en) Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis
US20110076261A1 (en) Antifungal Drug Delivery System
WO2014041542A2 (en) Topical compositions for the treatment of acne
CN111936130B (en) Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment
JPH07267869A (en) Remedy and method for medical treatment for dermatosis
US6485714B1 (en) Use of salicylic acid for regulating hyperpigmented spots
JP2002338426A (en) Keratin peeling promoter
JP2826142B2 (en) Dandruff inhibitor composition
WO1983000628A1 (en) A method of treating acne vulgaris and composition containing carbamide peroxide
WO2006119540A1 (en) Preparation for treating psoriasis
GB2275191A (en) Use of tolnaftate and tolciclate in treatment of skin disorder
JP2826141B2 (en) Dandruff inhibitor composition
GB2205743A (en) Cosmetic composition for prevention and/or treatment of dandruff
GB2302808A (en) Propylene glycol with low potency corticosteroids for topical treatment of the scalp
Stough et al. New beneficial agents in the treatment of acne vulgaris and seborrheic dermatitis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19960607

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SURTECH INTERNATIONAL LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970118